Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Juan Pablo Zarate
Novartis Pharmaceuticals Corporation
United States
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
82
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Number of pages: 22
Posted: 29 Oct 2020
Howard Burris
,
Arlene Chan
,
Aditya Bardia
,
J. Thaddeus Beck
,
Joohyuk Sohn
,
Patrick Neven
,
Debu Tripathy
,
Seock-Ah Im
,
Stephen Chia
,
Francisco J. Esteva
,
Lowell Hart
, Juan Pablo Zarate,
Antonia Ridolfi
,
Karen Rodriguez-Lorenc
and
Denise A. Yardley
Tennessee Oncology - Sarah Cannon Research Institute, Curtin University, Harvard Medical School - Massachusetts General Hospital Cancer Center, Highlands Oncology Group, Yonsei University Health System - Severance Hospital, KU Leuven - Department of Gynecologic Oncology, University of Texas at Houston - Department of Breast Medical Oncology, Seoul National University - Department of Internal Medicine, BC Cancer Agency (BCCA), NYU Langone Health, Sarah Cannon Research Institute - Florida Cancer Specialists, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation and Tennessee Oncology - Sarah Cannon Research Institute
Downloads
82
(790,029)
View PDF
Download
Abstract:
ribociclib, breast cancer, CDK4/6 inhibitor, endocrine therapy
Feedback